Roche Defends High Cancer Therapy Costs Amid Pricing Dispute
Roche is defending the high cost of a new cancer therapy, stating that decades of research and billions in investment were required. The company classifies the drug among the most innovative therapies available, noting that it is only suitable for approximately 20 patients in Switzerland annually.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
SRF 4 News
“Die Herstellerfirma Roche stellt sich auf den Standpunkt, dass die Forschung dafür Jahrzehnte lang dauerte, Milliarden kostete und das Medikament jetzt zu den neuartigsten, so genannt innovativen Therapien gehöre.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade